{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.5","value":"10.8"},{"groupId":"OG001","spread":"51.0","value":"10.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.7","value":"14.0"},{"groupId":"OG001","spread":"41.2","value":"14.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.2","value":"11.5"},{"groupId":"OG001","spread":"29.8","value":"12.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.5","value":"12.6"},{"groupId":"OG001","spread":"24.2","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.2","value":"13.5"},{"groupId":"OG001","spread":"23.2","value":"14.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"title":"Cycle 8 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"description":"Pre-dose plasma concentrations of fulvestrant were assessed.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Subjects with advanced breast cancer with or without a PIK3CA mutation treated with alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG000","title":"Alpelisib + Fulvestrant"},{"description":"Subjects with advanced breast cancer with or without a PIK3CA mutation treated with placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants who received at least one dose of fulvestrant and provided at least one evaluable trough plasma concentration for fulvestrant at the specified time points","reportingStatus":"POSTED","timeFrame":"Day 15 of Cycle 1, then Day 1 of Cycles 2, 4, 6 and 8. Cycle = 28 days","title":"Trough Plasma Concentration of Fulvestrant","type":"SECONDARY","unitOfMeasure":"nanogram (ng)/ milliliter (mL)"}